The therapy app for more air and health

Project Information

KATA

Grant agreement ID: 867249

DOI

10.3030/867249

Project closed

EC signature date 23 April 2019

Start date 1 May 2019

End date 31 August 2019

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

VISIONHEALTH GMBH
Germany

Periodic Reporting for period 1 - KATA (The therapy app for more air and health)

Reporting period: 2019-05-01 to 2019-08-31

Summary of the context and overall objectives of the project

Chronic respiratory diseases (CRDs), such as chronic obstructive pulmonary disease (COPD) and asthma, are the world’s fourth major health problem with 600 million people according to the World Health Organization (WHO). However, given the current number of cases, persistent smoking, aging population and the increasing levels of pollution in emerging countries, CRDs will become the third leading cause of death in the EU by 2030. Although CRDs patients are mostly treated with different inhalation devices, 90% of them are not using properly their inhalers which is essential to prevent exacerbations and decrease hospitalization and ED visits

Kata® app solution enhances inhalation therapy and trains CRDs patients with asthma or COPD to use their inhalers effectively, to improve their quality of life. The company behind Kata is VisionHealth, specialized in digital healthcare. Our mission consists in providing disruptive digital healthcare solutions for patients, to benefit from the full potential of their respiratory care. Our final goal is for respiratory patients to be liberated from their symptoms, enjoying life to the fullest and needing the healthcare system least.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

From a technical point of view, we have defined the technical process and optimization to evolve from a knowledge-based algorithm to a supervised machine learning driven approach in order to increase detection accuracy, while optimizing performance and usability of the software. We have elaborated a complete Execution Plan with a risk analysis and mitigation measures. Commercially, we have performed an analysis of our target markets, updated our business and revenue streams, and also consolidated our dissemination and commercial strategy. We have updated our Freedom-to-Operate analysis and a based line scenario and financial forecast has been drafted to evaluate a five year projection.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

CRDs are a huge economic burden comprising 78% of total direct healthcare costs associated to respiratory diseases in the EU. The annual costs of healthcare and lost productivity due to COPD are estimated as €48.4 billion and those due to asthma reach €33.9 billion euros. The global mHealth market is expected to reach €97B by 2025, growing at a CAGR of 44.2% with Europe and Asia Pacific leading the market.

Kata® will contribute to improve European and worldwide CRDs patient quality of life while reducing the economic burden and healthcare cost and increase working hours and productivity of patients. In addition, it will contribute to strengthen the leading position of Europe in the global mobile medical apps market.

image-1.png